🇺🇸 VRTX — Vertex Pharmaceuticals Incorporated
Salud CompraPrecio actual
549,04 USD
Máx. histórico
558,88
5 días
Split 2:1 del 24/08/2000
Caída desde máximo
-1,76%
Rango 52 semanas
406,67 – 568,67
Variación hoy
+3,44%
Cierre anterior
530,76
Rango de hoy
527,38 – 550,77
Volumen hoy
1.810.311
Peor caída histórica
-91,77%
02/11/2000 → 11/11/2003
Recuperado en 3885 días
Volatilidad anualizada ⓘ
54,63%
- Nombre completo
- Vertex Pharmaceuticals Incorporated
- Divisa
- USD
- Mercado
- NasdaqGS
- Sector
- Salud
- Industria
- Biotechnology
- Empleados
- 6.400
- PER ⓘ
- 36,82 (puede no estar actualizado)
- Dividend yield
- 0,00% (puede no estar actualizado)
- Precio objetivo analistas
- 578,71 USD (puede no estar actualizado)
- Primera cotización
- 24/07/1991
- Precio actualizado
- hace 17 horas
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. In addition, the company also operates as a clinical-stage pharmaceutical company, that focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated has a strategic collaboration with AbCellera Biologics Inc. to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
| Fecha | Ratio |
|---|---|
| 24/08/2000 | 2:1 |
| Fecha | Apertura | Máximo | Mínimo | Cierre | Variación | Volatilidad día | Volumen |
|---|---|---|---|---|---|---|---|
| 13/03/2001 | 32,25 | 36,19 | 32,13 | 35,75 | +11,72% | 12,60% | 1.421.700 |
| 12/03/2001 | 35,06 | 36,13 | 31,88 | 32,00 | -12,33% | 12,12% | 1.255.900 |
| 09/03/2001 | 38,00 | 41,00 | 36,25 | 36,50 | -8,32% | 12,50% | 1.262.300 |
| 08/03/2001 | 42,13 | 42,38 | 38,75 | 39,81 | -7,28% | 8,61% | 793.000 |
| 07/03/2001 | 44,81 | 45,00 | 41,19 | 42,94 | -4,85% | 8,51% | 1.137.800 |
| 06/03/2001 | 48,56 | 48,56 | 43,19 | 45,13 | -1,90% | 11,07% | 1.041.100 |
| 05/03/2001 | 47,06 | 49,19 | 45,13 | 46,00 | -2,26% | 8,63% | 535.000 |
| 02/03/2001 | 46,81 | 49,50 | 45,50 | 47,06 | -1,95% | 8,54% | 508.800 |
| 01/03/2001 | 49,13 | 49,88 | 45,64 | 48,00 | -3,52% | 8,62% | 906.100 |
| 28/02/2001 | 49,88 | 54,13 | 47,19 | 49,75 | -0,13% | 13,91% | 1.049.100 |
| 27/02/2001 | 55,00 | 56,25 | 49,50 | 49,81 | -11,25% | 12,27% | 879.900 |
| 26/02/2001 | 50,63 | 56,75 | 49,75 | 56,13 | +14,69% | 13,83% | 1.720.900 |
| 23/02/2001 | 46,06 | 49,13 | 44,75 | 48,94 | +2,49% | 9,50% | 2.268.300 |
| 22/02/2001 | 54,31 | 54,50 | 45,50 | 47,75 | -12,59% | 16,57% | 1.576.600 |
| 21/02/2001 | 51,00 | 56,25 | 50,63 | 54,63 | -0,46% | 11,03% | 1.039.900 |
| 20/02/2001 | 59,13 | 59,38 | 52,69 | 54,88 | -6,70% | 11,31% | 1.090.900 |
| 16/02/2001 | 58,88 | 61,00 | 56,00 | 58,81 | -7,11% | 8,49% | 1.337.900 |
| 15/02/2001 | 63,38 | 64,69 | 60,25 | 63,31 | +0,60% | 7,00% | 404.100 |
| 14/02/2001 | 60,63 | 63,50 | 58,38 | 62,94 | +3,39% | 8,45% | 858.700 |
| 13/02/2001 | 68,00 | 69,25 | 60,25 | 60,88 | -10,56% | 13,24% | 614.600 |
| 12/02/2001 | 62,81 | 68,25 | 61,88 | 68,06 | +7,11% | 10,15% | 492.000 |
| 09/02/2001 | 64,88 | 64,88 | 61,19 | 63,55 | -2,89% | 5,68% | 396.800 |
| 08/02/2001 | 64,06 | 65,75 | 62,63 | 65,44 | +4,08% | 4,88% | 786.900 |
| 07/02/2001 | 66,88 | 67,06 | 62,27 | 62,88 | -5,81% | 7,17% | 723.300 |
| 06/02/2001 | 62,31 | 69,00 | 62,25 | 66,75 | +9,20% | 10,83% | 1.046.700 |
| 05/02/2001 | 59,88 | 61,63 | 58,64 | 61,13 | +2,09% | 4,98% | 513.800 |
| 02/02/2001 | 63,13 | 63,88 | 59,88 | 59,88 | -5,62% | 6,34% | 648.600 |
| 01/02/2001 | 67,00 | 67,94 | 62,81 | 63,44 | -5,76% | 7,65% | 636.300 |
| 31/01/2001 | 69,50 | 71,88 | 67,25 | 67,31 | -1,17% | 6,65% | 647.700 |
| 30/01/2001 | 73,81 | 74,63 | 67,75 | 68,11 | -8,19% | 9,31% | 620.000 |